SUBQ: 3% to 9%), eructation (adolescents and adults: 7%), flatulence (1% to 6%), gastritis (2% to 4%), gastroenteritis (SUBQ: Adolescents and adults: 6% to 7%), gastroesophageal reflux disease (adolescents and adults: 2% to 5%), viral gastroenteritis (SUBQ: 4%) Nervous system : Fatigue (SUBQ: 11%), headache (SUBQ: Adolescents and adults: 14% to 17%), Anxiety (SUBQ: Adolescents: 4%), dizziness (SUBQ: Adolescents and adults: 8%) Respiratory: Nasopharyngitis (SUBQ: Adolescents: 12%), Sinusitis (SUBQ: Adolescents: 4%) Cardiovascular: Hypotension (SUBQ: Adolescents and adults: 1% to 2%
doi: 10.5530/jcdr.2015.1.5 547 LanZTanFHeJLiuJLuMHuZet al
1995, 44 (10 Suppl 4): 50-57
Note: Any adverse reactions should be reported via the Yellow Card scheme
Weber et al, 2023]) and to interact with the runt family transcription factor RUNX2 via its carboxy-terminal methionine- and serine-rich regions (Pelletier et al, 2002)